Aktiesnakken — Juni 2010
-
Måske er genmab blevet max shortet idag... ufff da, har i tænkt på det?
-
mit bud for imorgen er at den falder 3-5%
-
-
AU : Desuden ser vi det for første gang som en reel mulighed, at den globale Arzerra-partner GSK vil afgive købstilbud på Genmab. Et sådant købstilbud forventer vi vil ligge i intervallet 150-200 kr. per aktie, skriver Peter Aabo fra Biotekanalyse.d
-
Det mener man ellers her f.eks http://npinvestor.dk/nyheder/aktier-flot-dag-for-c20-genmab-steg-33-pct-206786.aspx
-
jeg ved at danske e
-
reagerer på AU på biotek
-
men kan forklaringen ikke koges ned til au+short lukning
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind